Bioavailability of a BCS class II substance can be highly affected by its formulation design. In this respect, solid dispersion in a hydrophilic carrier formulation was introduced a decade ago to resolve the problem of BCS class II substance. With that, several processing methods of the solid dispersion have been studied. Amongst the advent processing methods hot melt extrusion (HME) has appeared as a robust manufacturing method in formulating solid dispersion. The use of this method offers many advantages as compared to the other conventional methods such as environmental friendly, cost sparing and readily scalable. This review explores the use of hot melt extrusion in the preparation of solid dispersion. Besides, current trend of the investigated active pharmaceutical ingredient (API) and the recommended carrier used in this manufacturing process were summarized and categorized. Other concerns regarding the use various excipients and additives were also investigated and grouped into easily accessible format such as table. Alongside to the review, results drawn from the literature regarding the performance of the obtained HME based solid dispersion were also discussed.
Comments
Add comment